• Início
  • Resultados da busca
  • Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

JAMA (2014-11-18)
Mikhail Kosiborod, Henrik S Rasmussen, Philip Lavin, Wajeh Y Qunibi, Bruce Spinowitz, David Packham, Simon D Roger, Alex Yang, Edgar Lerma, Bhupinder Singh
RESUMO

Hyperkalemia is a common electrolyte abnormality that may be difficult to manage because of a lack of effective therapies. Sodium zirconium cyclosilicate is a nonabsorbed cation exchanger that selectively binds potassium in the intestine. To evaluate the efficacy and safety of zirconium cyclosilicate for 28 days in patients with hyperkalemia. HARMONIZE was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating zirconium cyclosilicate in outpatients with hyperkalemia (serum potassium ≥5.1 mEq/L) recruited from 44 sites in the United States, Australia, and South Africa (March-August 2014). Patients (n = 258) received 10 g of zirconium cyclosilicate 3 times daily in the initial 48-hour open-label phase. Patients (n = 237) achieving normokalemia (3.5-5.0 mEq/L) were then randomized to receive zirconium cyclosilicate, 5 g (n = 45 patients), 10 g (n = 51), or 15 g (n = 56), or placebo (n = 85) daily for 28 days. The primary end point was mean serum potassium level in each zirconium cyclosilicate group vs placebo during days 8-29 of the randomized phase. In the open-label phase, serum potassium levels declined from 5.6 mEq/L at baseline to 4.5 mEq/L at 48 hours. Median time to normalization was 2.2 hours, with 84% of patients (95% CI, 79%-88%) achieving normokalemia by 24 hours and 98% (95% CI, 96%-99%) by 48 hours. In the randomized phase, serum potassium was significantly lower during days 8-29 with all 3 zirconium cyclosilicate doses vs placebo (4.8 mEq/L [95% CI, 4.6-4.9], 4.5 mEq/L [95% CI, 4.4-4.6], and 4.4 mEq/L [95% CI, 4.3-4.5] for 5 g, 10 g, and 15 g; 5.1 mEq/L [95% CI, 5.0-5.2] for placebo; P < .001 for all comparisons). The proportion of patients with mean potassium <5.1 mEq/L during days 8-29 was significantly higher in all zirconium cyclosilicate groups vs placebo (36/45 [80%], 45/50 [90%], and 51/54 [94%] for the 5-g, 10-g, and 15-g groups, vs 38/82 [46%] with placebo; P < .001 for each dose vs placebo). Adverse events were comparable between zirconium cyclosilicate and placebo, although edema was more common in the 15-g group (edema incidence: 2/85 [2%], 1/45 [2%], 3/51 [6%], and 8/56 [14%] patients in the placebo, 5-g, 10-g, and 15-g groups). Hypokalemia developed in 5/51 (10%) and 6/56 patients (11%) in the 10-g and 15-g zirconium cyclosilicate groups, vs none in the 5-g or placebo groups. Among outpatients with hyperkalemia, open-label sodium zirconium cyclosilicate reduced serum potassium to normal levels within 48 hours; compared with placebo, all 3 doses of zirconium cyclosilicate resulted in lower potassium levels and a higher proportion of patients with normal potassium levels for up to 28 days. Further studies are needed to evaluate the efficacy and safety of zirconium cyclosilicate beyond 4 weeks and to assess long-term clinical outcomes. clinicaltrials.gov Identifier: NCT02088073.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Potassium, chunks (in mineral oil), 98% trace metals basis
Sigma-Aldrich
Aldosterone, ≥95% (HPLC)
Sigma-Aldrich
Potassium hydride, 30 wt % dispersion in mineral oil
Sigma-Aldrich
Glycine ethyl ester hydrochloride, 99%
Sigma-Aldrich
Potassium, cubes (in mineral oil), 99.5% trace metals basis
Sigma-Aldrich
Zirconium, powder, −100 mesh
Sigma-Aldrich
Potassium hydride, in paraffin
Sigma-Aldrich
Zirconium, sponge, ≥99% trace metals basis
Sigma-Aldrich
β-D-Allose, rare aldohexose sugar
Sigma-Aldrich
Zirconium, rod, diam. 6.35 mm, ≥99% trace metals basis
Zirconium, foil, light tested, 25x25mm, thickness 0.02mm, 99.2%
Zirconium, rod, 200mm, diameter 3.0mm, centerless ground, 99.2%
Zirconium, foil, not light tested, 50x50mm, thickness 0.006mm, 99.2%
Zirconium, rod, 1000mm, diameter 12.7mm, centerless ground, 99.2%
Zirconium, rod, 1000mm, diameter 2.0mm, centerless ground, 99.2%
Zirconium, rod, 1000mm, diameter 3.0mm, centerless ground, 99.2%
Zirconium, rod, 1000mm, diameter 5.0mm, centerless ground, 99.2%
Zirconium, rod, 1000mm, diameter 9.5mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 12.7mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 19.0mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 2.0mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 3.0mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 5.0mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 50mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 9.5mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 19.0mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 2.0mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 5.0mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 9.5mm, centerless ground, 99.2%
Zirconium, rod, 500mm, diameter 12.7mm, centerless ground, 99.2%